shape Monitor
Angela Vasaturo, PhD; Julia Katerina Schwarze, MD

Associate Director Scientific Affairs, Ultivue; Dept of Medical Oncology, University Hospital Brussels

Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors

Length: 60 minutes

Relevant for

FixVUE, InSituPlex

Description In this exciting webinar co-hosted by GEN and Clinical OMICs, we explored the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we heard how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.

Meet the host

Angela Vasaturo is the Associate Director Scientific Affairs at Ultivue. Prior to joining Ultivue she was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Centre. She has a wealth of expertise in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.

Angela Vasaturo, PhD

Associate Director Scientific Affairs, Ultivue

Julia Katerina Schwarze, MD

Dept of Medical Oncology, University Hospital Brussels